A viral interview clip has been circulating with a striking claim: some people with severe cognitive impairment were reportedly unable to perform basic tasks such as tying their shoes or drawing a clock, yet later regained those abilities after their bodies began producing more ketones.
It is the kind of statement that immediately sounds extraordinary.
But there is a real scientific question underneath it.
For more than two decades, researchers have been studying whether ketones, which the brain can use as an alternative fuel source, might improve certain aspects of cognition in people with mild cognitive impairment or Alzheimer’s disease.
Some of those findings are genuinely intriguing.
What the evidence does not show, however, is that ketosis routinely restores lost abilities within hours or reverses Alzheimer’s disease.
Why ketones are being studied in Alzheimer’s disease
The brain normally relies heavily on glucose for energy.
When carbohydrate availability falls significantly, such as during fasting or a ketogenic diet, the liver begins producing more ketone bodies, including beta-hydroxybutyrate and acetoacetate.
These molecules can cross the blood-brain barrier and be used by the brain for energy.
That becomes particularly interesting in Alzheimer’s disease because the condition is associated with changes in cerebral glucose metabolism. Brain imaging studies have repeatedly shown reduced glucose use in specific regions affected by the disease.
At the same time, the brain’s ability to use ketones may remain comparatively preserved.
This has led researchers to ask a simple but important question: if part of the brain’s normal energy system is impaired, could providing an alternative fuel help neurons function better?
The idea is biologically plausible, and it is supported by experimental research.
A small study found cognitive changes within about 90 minutes
One frequently cited study was published in Neurobiology of Aging in 2004.
Researchers studied 20 adults with probable Alzheimer’s disease or mild cognitive impairment and gave them medium-chain triglycerides, better known as MCTs.
MCTs can be rapidly metabolized by the liver and increase circulating ketone levels.
About 90 minutes after administration, blood beta-hydroxybutyrate levels were significantly higher.
Researchers also detected changes in cognitive performance. In particular, some participants showed improvement on the ADAS-Cog assessment, and higher ketone levels were associated with better performance on a memory task.
That matters because it suggests that raising ketone availability can produce measurable cognitive effects relatively quickly.
But the study did not show that people who could no longer tie their shoes suddenly regained that ability within 90 minutes.
It also did not show that someone who could not draw a clock immediately began drawing one normally.
Those dramatic examples come from a different body of evidence.
The story behind the famous clock drawings
One of the best-known individual cases in the ketogenic-Alzheimer’s discussion is that of Steve Newport.
His wife, physician Mary Newport, began giving him dietary fats intended to raise ketone production after he had developed early-onset Alzheimer’s disease.
One part of his story became especially well known: a series of clock drawings.
Before the intervention, he reportedly produced a highly disorganized drawing during cognitive testing. Later drawings appeared much more structured, with a clearer circle and better placement of numbers.
Those images became widely circulated as visual evidence that something had changed.
But the timeline matters.
The better-known improvement in the clock drawing did not happen within a few hours. It was documented over a period of days to weeks.
Steve Newport was later given an experimental ketone ester, and a published case report described improvements in several areas, including mood, interaction, daily functioning and cognitive performance.
That report remains interesting.
It is also still a single case.
Case reports are useful for generating research questions, but they cannot establish that a treatment will work in the same way for other patients.
What about the claim that patients could tie their shoes again?
Reports involving regained daily skills do exist in ketogenic and MCT-related case descriptions.
Caregivers have described improvements in dressing, communication, self-care and other practical activities.
Some reports have also included dramatic examples such as a person regaining the ability to tie shoes.
The problem is that anecdotal reports are not equivalent to controlled clinical trials.
They may reflect genuine changes, but they cannot reliably tell us how much of the improvement came from the intervention, whether the change would have happened anyway or how likely the same response is in another patient.
This is where viral clips often blur the boundaries.
A rapid cognitive change from one study, a clock drawing from one case and a story about regained daily skills from another source can easily be compressed into one dramatic narrative.
Scientifically, they should remain separate.
Larger clinical studies have also found encouraging signals
The research is not limited to isolated case reports.
In 2009, a randomized, double-blind, placebo-controlled multicenter trial evaluated a ketogenic compound known as AC-1202 in 152 people with mild to moderate Alzheimer’s disease.
The intervention raised ketone levels and produced statistically significant differences in ADAS-Cog scores in some analyses compared with placebo.
The effects appeared stronger among participants who did not carry the APOE ε4 allele.
Other randomized studies using MCTs have also reported cognitive benefits, again with some evidence that APOE status may influence the response.
This pattern has attracted serious scientific interest because it suggests that metabolic interventions may not work equally well in everyone.
A six-month trial also reported improvements
Another important piece of evidence comes from the BENEFIC trial.
People with mild cognitive impairment consumed either a ketogenic MCT drink or a placebo drink for six months.
Researchers reported improvements in several cognitive domains, including episodic memory, executive function and language.
Importantly, this kind of study provides stronger evidence than a case report because it includes a comparison group and follows participants over time.
Even so, improvement on cognitive testing does not mean the underlying neurodegenerative disease has been cured.
That distinction is essential.
What happens when the ketogenic diet itself is tested?
Not all ketogenic interventions are the same.
Taking MCTs or ketone esters is different from following a strict ketogenic diet.
A ketogenic diet requires a substantial reduction in carbohydrate intake and often produces a deeper, more sustained state of ketosis.
That approach has also been studied.
In a randomized crossover trial published in 2021, people with Alzheimer’s disease followed either a modified ketogenic diet or a control diet for 12 weeks.
The ketogenic phase was associated with improvements in daily functioning and quality of life.
Cognitive scores also moved in a favorable direction, although the difference on the main cognitive measure did not reach the threshold for statistical significance.
That result is a good example of why the topic deserves careful wording.
It is reasonable to say that the intervention showed promising effects.
It would not be reasonable to say that the diet reversed Alzheimer’s disease.
A remarkable case involving Down syndrome and Alzheimer’s disease
Another case report attracted attention because of the size of the reported change.
A 47-year-old woman with Down syndrome, Alzheimer’s disease and seizure activity had experienced progressive cognitive decline over several years.
After beginning a therapeutic ketogenic diet, her family and clinicians reported substantial improvement in daily functioning, cognition, mood and behavior over several weeks.
Her score on one measure of everyday functioning rose markedly.
The case is clinically interesting because people with Down syndrome have an especially high risk of developing Alzheimer-related brain changes.
But again, a single case cannot establish a general treatment effect.
It can show that further research is justified.
It cannot tell us how most patients will respond.
Is Alzheimer’s simply a problem of insulin being unable to get glucose into the brain?
This is one area where popular explanations often become too simplistic.
Alzheimer’s disease is sometimes referred to informally as “type 3 diabetes,” and the explanation is occasionally reduced to the idea that the brain becomes insulin-resistant, glucose can no longer enter neurons properly and ketones bypass the problem.
The biology is more complicated than that.
Most glucose transport into the brain does not depend on insulin in the same way that glucose uptake in muscle or fat tissue does.
GLUT1 plays a major role in transporting glucose across the blood-brain barrier, while GLUT3 is an important neuronal glucose transporter. These transporters are not primarily insulin-dependent.
That does not mean insulin is irrelevant in the brain.
Insulin signaling affects many neurological processes, and impaired brain insulin signaling remains an important research area in Alzheimer’s disease.
But saying that insulin simply “stops opening the door” for glucose is not an accurate description of what is happening.
Researchers have also found alterations in glucose transporters and other components of cerebral energy metabolism in Alzheimer’s disease.
The metabolic problem is real, but it is multifactorial.
So why might ketones still help?
Because ketones reach the brain through different metabolic pathways and can serve as an additional energy substrate.
Some studies suggest that ketone use remains relatively intact even when cerebral glucose metabolism is reduced.
That means ketones may provide extra usable energy to neurons that are still alive but functioning under metabolic stress.
Researchers are also investigating possible effects of beta-hydroxybutyrate beyond simple energy production, including influences on mitochondrial function, inflammation, oxidative stress and cellular signaling.
These mechanisms are scientifically plausible.
Most are still being actively studied.
Better cognitive performance is not the same as reversing Alzheimer’s disease
This may be the most important point of all.
Suppose a person with Alzheimer’s disease performs better on a memory test after a ketogenic intervention.
That improvement can be real and clinically meaningful.
But it does not automatically mean that the disease process has stopped.
Alzheimer’s disease involves complex changes including amyloid pathology, tau abnormalities, synaptic dysfunction, inflammation and progressive neuronal loss.
A treatment could potentially help surviving neurons function more efficiently without removing the underlying pathology.
In practical terms, symptom improvement and disease reversal are not the same thing.
This distinction is often lost in social media discussions.
Why APOE status may matter
The APOE gene appears repeatedly in this research.
The APOE ε4 allele is the strongest common genetic risk factor for late-onset Alzheimer’s disease.
Several studies of MCTs and ketogenic interventions have reported stronger cognitive responses among participants who did not carry APOE ε4.
That does not mean APOE status can yet be used as a simple yes-or-no test for ketogenic treatment.
It does mean that individual biology may strongly influence the response.
This is another reason broad claims about what ketosis does “for the brain” should be treated cautiously.
Different patients may respond very differently.
Does ketosis make healthy people smarter?
That is a separate question, and the evidence is much weaker.
A metabolic strategy that may help compensate for impaired brain energy use in a neurological disease does not automatically enhance the performance of a healthy brain.
Research in healthy adults has produced mixed results.
Some studies suggest possible effects on attention, energy or certain cognitive tasks, while others find little or no meaningful benefit.
At present, there is no strong evidence that entering ketosis reliably makes healthy adults more intelligent.
The Alzheimer’s research should not be used to make that claim.
Should someone with Alzheimer’s disease start a ketogenic diet?
Not on the basis of a viral video.
The studies discussed here used different interventions, including MCTs, ketone-producing compounds, ketone esters and ketogenic diets.
Those approaches are not interchangeable.
A strict ketogenic diet can also be difficult to maintain, especially in older adults and people with dementia.
Weight loss, dehydration, reduced food intake, gastrointestinal symptoms and nutritional deficiencies can become important concerns.
Some ketogenic approaches may also affect blood lipids.
For a person with Alzheimer’s disease, any major dietary intervention should therefore be discussed with a physician and, ideally, a dietitian familiar with therapeutic ketogenic protocols.
So is the viral claim true or false?
The most accurate answer is that it contains a real scientific idea but presents it in a way that makes the evidence sound more dramatic and certain than it currently is.
There are controlled studies showing cognitive changes after ketone levels are increased.
There are longer trials reporting improvements in certain cognitive domains.
There are also striking individual cases in which patients reportedly regained aspects of daily functioning.
What we do not have is evidence that putting a person with advanced cognitive impairment into ketosis routinely causes lost abilities such as tying shoelaces or drawing a clock to return within hours.
That leap goes beyond what the research has established.
The real science is interesting enough without turning it into a miracle
The most compelling part of this story is not the suggestion that a dietary intervention has secretly solved Alzheimer’s disease.
It has not.
The more interesting possibility is that energy metabolism may be one important piece of the Alzheimer’s puzzle.
If the diseased brain is using glucose less effectively while remaining capable of using ketones, researchers may have an opportunity to support brain function through an alternative metabolic pathway.
Clinical studies have already produced enough encouraging results to justify further research.
What remains unclear is who benefits most, which ketogenic strategy works best, how long the effects last and whether these interventions can influence disease progression rather than only improve symptoms.
Those are major unanswered questions.
For now, ketosis should not be presented as a cure for Alzheimer’s disease.
But the possibility that changing the brain’s available fuel can influence cognition is a legitimate and increasingly important area of neurological research.
And that scientific reality is far more interesting than a viral promise.
Sources
Reger MA et al. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiology of Aging, 2004.
Henderson ST et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutrition & Metabolism, 2009.
Fortier M et al. A ketogenic drink improves cognition in mild cognitive impairment: Results of a 6-month RCT. Alzheimer’s & Dementia, 2021.
Phillips MCL et al. Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease. Alzheimer’s Research & Therapy, 2021.
Croteau E et al. Ketogenic Medium Chain Triglycerides Increase Brain Energy Metabolism in Alzheimer’s Disease. Journal of Alzheimer’s Disease, 2018.
Avgerinos KI et al. Medium Chain Triglycerides induce mild ketosis and may improve cognition in Alzheimer’s disease. Ageing Research Reviews, 2020.
Sun L et al. The Effects of Medium Chain Triglyceride for Alzheimer’s Disease Related Cognitive Impairment: A Systematic Review and Meta-Analysis. Journal of Alzheimer’s Disease, 2023.
Newport MT et al. A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer’s disease. Alzheimer’s & Dementia, 2015.
Bosworth A et al. Case report: Ketogenic diet acutely improves cognitive function in patient with Down syndrome and Alzheimer’s disease. Frontiers in Psychiatry, 2023.
Kyrtata N et al. A Systematic Review of Glucose Transport Alterations in Alzheimer’s Disease. Frontiers in Neuroscience, 2021.